Kapil Tuladhar
Home / People / Kapil Tuladhar

Kapil Tuladhar

Associate, European and UK Patent Attorney, European Patent Litigator

Kapil is a European and UK Patent Attorney. He secures patent protection for a range of clients, acting principally before the European Patent Office (EPO) and with a focus on the life sciences. He drafts, files and prosecutes patent applications, including cases relating to cell and gene therapy, microvesicles, microbiology and oligonucleotide technology. He also understands the needs of companies at different stages of the business life cycle, including the specific needs of startups and academic spin-outs.

Following on from doctoral research into the development and molecular programming of blood, Kapil has an interest in patent work in the area of stem cells, acting in particular for UK-, US-, and Japanese-based companies and academic institutions. In this regard, he handles a variety of stem cell technologies, for example relating to the production of various tissues from reprogrammed cells and associated therapeutics. He also has a keen interest in climatetech and innovations to help combat climate change, in particular, working to help secure protection for a successful carbon capture company.

Kapil has successfully defended patents before the EPO’s Opposition Division and Boards of Appeal, including as lead advocate and as part of a large team on a high-profile case involving parallel national infringement proceedings. He has also been involved in providing Freedom to Operate opinions. Further afield, Kapil has directed large worldwide patent filing and surveillance programmes, covering both major and more esoteric markets.

Within J A Kemp, Kapil advises on issues relating to the depositing of biological material under the Budapest Treaty. He also has responsibility for the firm’s relationships with Israel.

Kapil is based at our Oxford office and is a mentor for a number of local entrepreneurship and accelerator programmes.

Kapil joined J A Kemp in 2012 and became an associate in 2019.